DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
DarioHealth Corp.NASDAQ: DRIO
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit declines year over year
Q1 FY2026 gross profit of $3.2M fell 17.6% year over year, ahead of the -35.5% change in trailing-twelve-month gross profit. Sequentially, it rose 35.0% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Gross profit amounted to 56.6% of revenue in FY2025, up 7.6 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -17.6% holds above the trailing-twelve-month pace of -35.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 12.67M USD
- Year-over-year change
- -4.5%
- 4-year CAGR
- +11.9%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.67M | -4.5% |
| FY2024 | 2024-12-31 | 13.27M | +121.7% |
| FY2023 | 2023-12-31 | 5.98M | -38.0% |
| FY2022 | 2022-12-31 | 9.66M | +19.7% |
| FY2021 | 2021-12-31 | 8.07M | — |
Gross Profit vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 gross profit of $11.98M is the 8th highest of the 11 companies compared; the peer median is $91.68M.
- Its year-over-year change of -35.5% is the 10th highest of 11, against a peer median of +20.5%.
- Gross profit amounts to 56.5% of revenue for DRIO, versus a peer median of 58.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $580M | -0.3% | +6.6% | 70.0% | |
| LTM Mar 2026 | $569.63M | +5.4% | +17.8% | 69.0% | |
| LTM Mar 2026 | $347.6M | -7.9% | -4.0% | 48.6% | |
| LTM Mar 2026 | $196.25M | +31.8% | +62.9% | 20.7% | |
| LTM Mar 2026 | $124.02M | +9.3% | -29.1% | 38.7% | |
| LTM Mar 2026 | $59.34M | +140.9% | +1.1% | 37.1% | |
| LTM Mar 2026 | $41.53M | +315.3% | +114.5% | 83.7% | |
| LTM Mar 2026 | $11.98M | -35.5% | +9.5% | 56.5% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $8.51M | +44.6% | -12.2% | 87.2% |
| LTM Mar 2026 | -$120K | -100.1% | +37.2% | 0.1% | |
| LTM Mar 2026 | -$24.18M | +48.7% | — | 1316.9% | |
| Peer median (excluding DRIO) | $91.68M | +20.5% | +6.6% | 58.8% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.